P0155 Effect of pretreatment anaemia on outcomes of Chinese women with breast cancer receiving neoadjuvant chemotherapy

Abstract

Background Anaemia related to adjuvant chemotherapy might predict worse survival in patients with breast cancer. The present population-based study investigated the effect of pretreatment anaemia on pathological response and long-term prognosis of breast cancer patients receiving neoadjuvant chemotherapy. Methods From 1999 to 2011, 655 patients with operable or locally advanced breast cancer who underwent neoadjuvant chemotherapy before definitive surgery were reviewed. The patients were subdivided into anaemic (baseline haemoglobin [Hb] Findings 166 women (25.3%) were anaemic before treatment. Patients in the anaemic group were less likely to achieve pCR after neoadjuvant chemotherapy than their non-anaemic counterparts (odds ratio 0.428, 95% confidence interval (CI) 0.198–0.927, p = 0.031). Patients with baseline anaemia displayed inferior 10-year RFS (59.1% versus 66.0%, p = 0.022 by log-rank), OS (75.3% versus 90.9%, p p p = 0.007), cancer-specific mortality (hazard ratio 3.152, 95% CI 1.784–5.569, p p Interpretation Pretreatment anaemia exerted a moderately adverse effect on pathological response to neoadjuvant chemotherapy as well as survival status in breast cancer. Further studies are warranted to optimise the treatment of cancer-related anaemia and improve the prognosis of this subgroup of patients.